CLLS
Cellectis S.A.
NASDAQ · Healthcare · Biotechnology · FR
$3.24
−2.41%Margins
Gross margin
74.7%
EBITDA margin
-98.1%
EBIT margin
-109.3%
Net margin
-115.5%
FCF margin
-77.9%
-159.1%
Return on equity
-24.4%
Return on assets
-49.2%
Return on invested capital
0.20x
Asset turnover
-$41.9M
Cash from operations
$1.66
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026